What non‑hormonal medications are similar to Veozah (fezolinetant) for treating moderate‑to‑severe vasomotor symptoms in menopausal women?

Non-Hormonal Medications Similar to Veozah for Menopausal Vasomotor Symptoms

The primary non-hormonal medications similar to Veozah (fezolinetant) for treating moderate-to-severe vasomotor symptoms include SNRIs (particularly venlafaxine), SSRIs (paroxetine), gabapentin, pregabalin, and the newer NK receptor antagonist elinzanetant, with elinzanetant showing the most comparable efficacy to fezolinetant. 1

First-Line Non-Hormonal Alternatives

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Venlafaxine is the most extensively studied and recommended SNRI for vasomotor symptoms:

• Dosing: 37.5-75 mg daily, with 75 mg being the optimal dose 1
• Efficacy: Reduces hot flash scores by 61% at 75 mg/day compared to 27% with placebo 1
• Onset: Faster effect than clonidine, though less well tolerated 1
• Side effects: Dry mouth, decreased appetite, nausea, constipation (dose-related) 1
• Guideline support: Recommended by ASCO, NCCN, and American Cancer Society as first-line non-hormonal therapy 1

Desvenlafaxine (50-200 mg) is another SNRI option, though fezolinetant shows superior efficacy in reducing VMS frequency compared to all desvenlafaxine doses 2

SSRIs (Selective Serotonin Reuptake Inhibitors)

Paroxetine is the only FDA-approved SSRI for vasomotor symptoms:

• Dosing: 7.5 mg daily (low-dose formulation) 1
• Efficacy: Reduces hot flash composite score by 62-65% 1
• Important caveat: Should be used with caution in women taking tamoxifen due to CYP2D6 inhibition, which may reduce tamoxifen conversion to active metabolites 1
• Comparative efficacy: Fezolinetant 45 mg significantly outperforms paroxetine 7.5 mg, with a mean difference of 1.66 additional VMS reductions per day 2

Other SSRIs (fluoxetine, citalopram, sertraline) have been studied but show variable results and are not FDA-approved for this indication 1

Anticonvulsants

Gabapentin is a well-established alternative:

• Dosing: 900 mg/day (typically divided doses) 1
• Efficacy: Decreases hot flash severity score by 46% at 8 weeks versus 15% with placebo 1
• Advantage: Somnolence side effect can be beneficial when given at bedtime for patients with hot flash-disturbed sleep 1
• Comparative efficacy: Fezolinetant 45 mg shows significantly greater reduction in VMS frequency (mean difference 1.63 events/day) compared to gabapentin ER 1800 mg 2

Pregabalin has also demonstrated efficacy for menopause-related vasomotor symptoms, though with similar side effect profile to gabapentin 1

Antihypertensives

Clonidine (alpha-agonist):

• Efficacy: Can reduce hot flash frequency and severity in postmenopausal women, including those on tamoxifen 1
• Side effects: Sleep difficulties, dry mouth, fatigue, dizziness, nausea, hypotension, light-headedness 1
• Important warning: Sudden cessation can lead to significant blood pressure elevations 1
• Comparative profile: Slower onset but better tolerated than venlafaxine 1

Emerging NK Receptor Antagonist

Elinzanetant (NK1 and NK3 receptor antagonist):

• Dosing: 120 mg shows optimal efficacy 3, 4
• Mechanism: Dual NK1/NK3 receptor antagonist (compared to fezolinetant's selective NK3 antagonism) 5
• Efficacy advantages over fezolinetant:
  • Larger effect size in VMS frequency reduction (mean difference 2.99 vs 2.54 for fezolinetant 45 mg) 3
  • Greater VMS severity reduction (mean difference 0.36 vs 0.24 for fezolinetant 45 mg) 3
  • Significant improvement in sleep quality (mean difference 4.65) 3
• Safety profile: More favorable than fezolinetant, with lower rates of drug-related adverse events (20.75% vs fezolinetant) and headache (8.0% vs lower rates) 3
• Status: Recently approved as a non-hormonal treatment option 5

Comparative Efficacy Framework

Relative to Fezolinetant

Fezolinetant demonstrates superior efficacy to all traditional non-hormonal therapies:

• Significantly more effective than paroxetine 7.5 mg, all desvenlafaxine doses (50-200 mg), and gabapentin ER 1800 mg in reducing VMS frequency 2
• Does not differ significantly from hormone therapy regimens available in the United States 2
• Reduces moderate-to-severe VMS by 2.1-2.6 events per day more than placebo at weeks 4 and 12 6

Elinzanetant shows comparable or superior efficacy to fezolinetant:

• Provides larger effect sizes in both frequency and severity reduction 3, 4
• Better improvement in menopause-specific quality of life 4

Clinical Decision Algorithm

For women requiring non-hormonal therapy:

1. First consideration: Assess contraindications and patient preferences

   • Women on tamoxifen: Avoid paroxetine; prefer venlafaxine, gabapentin, or fezolinetant 1
   • Women with sleep disturbances: Consider gabapentin (bedtime dosing) or elinzanetant 1, 3
   • Women with hypertension concerns: Avoid clonidine 1

2. Efficacy hierarchy (based on VMS frequency reduction):

   • Highest efficacy: Elinzanetant 120 mg > Fezolinetant 45 mg 3, 4
   • Moderate efficacy: Venlafaxine 75 mg, Gabapentin 900 mg 1, 2
   • Lower efficacy: Paroxetine 7.5 mg, Desvenlafaxine, Clonidine 2

3. Cost and access considerations: Traditional agents (venlafaxine, gabapentin, paroxetine) are generally more accessible and affordable than NK receptor antagonists 7, 8

Important Caveats

Monitoring Requirements

Fezolinetant requires hepatic monitoring:

• Liver function tests before initiation, monthly for first 3 months, then at 6 and 9 months 6
• Real-world data shows only 42% of persistent users received appropriate liver function testing 8

Discontinuation Considerations

• SNRIs and SSRIs: Must be gradually tapered to minimize withdrawal symptoms 1
• Clonidine: Gradual taper essential to prevent rebound hypertension 1

Special Populations

Breast cancer survivors:

• NCCN prefers non-hormonal options as first-line therapy 1
• Avoid paroxetine in women on tamoxifen 1
• Real-world data shows 20.5% of fezolinetant users have breast cancer diagnosis 8

Women over 65:

• Comprised 13.3% of real-world fezolinetant users despite exclusion from initial trials 8
• Post-marketing safety data needed for this population 8

Persistence and Real-World Use

• Only 20.5% of fezolinetant users demonstrate persistent use (defined as second prescription within 28-90 days) 8
• Uptake has increased over time, from 233 prescriptions in May-July 2023 to 1,871 in May-July 2024 8